Form 4: USPH COO Sells 662 Shares; Retains 30,078

U.S. Physical Therapy's COO, Graham D. Reeve, reported the sale of 662 common shares at a weighted average price of $78.86, while retaining a significant holding.

Summary

• Graham D. Reeve, Chief Operating Officer of U.S. Physical Therapy, Inc. (USPH), sold 662 shares of common stock.
• The shares were sold on March 11, 2026, at a weighted average price of $78.86 per share.
• The sale price ranged from $78.82 to $79.82 per share.
• Following this transaction, Mr. Reeve directly beneficially owns 30,078 shares of common stock.
• This remaining ownership includes 21,384 restricted shares granted under the Company's Amended and Restated 2003 Stock Incentive Plan.
• These restricted shares have a vesting schedule extending from May 20, 2026, through March 6, 2030, contingent on Mr. Reeve's continued employment.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale can sometimes be perceived negatively, the small number of shares sold relative to the COO's total holdings and the long-term vesting schedule of remaining restricted stock suggest this is likely for personal liquidity rather than a bearish signal.

Positives

• The COO retains a substantial holding of 30,078 shares, including 21,384 restricted shares, indicating continued alignment with shareholder interests.
• The vesting schedule for restricted stock through March 2030 suggests long-term commitment to the company.

Negatives

• An insider sale, even of a relatively small number of shares (662 shares), could be perceived negatively by some investors, potentially signaling a lack of confidence or a need for liquidity.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, particularly from C-suite executives, are routinely monitored by investors for signals regarding management's perception of future company performance. In the healthcare services sector, especially physical therapy, executive stock transactions can reflect views on reimbursement trends, regulatory changes, or competitive landscape shifts. This specific sale is relatively small compared to the executive's total holdings, suggesting it may be for personal liquidity rather than a bearish signal on the company's prospects.

Comparison to Industry Standards

• Insider selling is a common occurrence across all industries, often for personal financial planning, tax obligations, or diversification.
• Compared to other healthcare executives, a sale of 662 shares from a total holding of over 30,000 shares is not unusually large or indicative of a significant shift in sentiment. For example, executives at larger healthcare providers like HCA Healthcare or Tenet Healthcare often report sales of thousands to tens of thousands of shares, making this a minor transaction in comparison.
• The retention of a substantial number of restricted shares with a long vesting schedule is standard practice for executive compensation plans aimed at aligning long-term interests.

Related Party Transactions

• The sale of common stock by the Chief Operating Officer is a related party transaction, as it involves an executive of the company.
• The granting of 21,384 restricted shares under the Company's Amended and Restated 2003 Stock Incentive Plan is also a related party transaction.

Stakeholder Impact

• Shareholders: May interpret the sale as a minor liquidity event or, for some, a slight negative signal, though the retained holdings suggest continued alignment.
• Employees: No direct impact mentioned. The COO's continued employment and vesting schedule indicate stability in leadership.
• Management: The COO's compensation structure, including restricted stock, remains in place, aligning his interests with long-term company performance.

Next Steps

• The remaining 21,384 restricted shares will vest according to a schedule from May 20, 2026, through March 6, 2030, contingent on continued employment.

Key Dates

Recommendation

The insider sale by the COO is a minor transaction relative to his overall holdings and the company's market capitalization. It does not provide a strong signal for either buying or selling the stock. The executive retains a substantial stake, including long-term restricted stock, suggesting continued alignment with the company's future. Therefore, a "hold" recommendation is appropriate, as this filing alone does not alter the fundamental investment thesis for USPH.

Keywords

USPH, U.S. Physical Therapy, insider trading, Form 4, stock sale, COO, Graham D. Reeve, restricted stock, equity compensation